



Ziftomenib | Menin-MLL1 PPI

oral menin-MLL1 inhibitor
Ph. I/II candidate in leukemia
from HTS and SBDD
Leukemia
Kura Oncology, San Diego, CA




GB1211 | Galectin-3

oral galectin-3 inhibitor
Ph. I/II candidate in cancer and liver diseases
LLE and PK opt. from a prev. clinical candidate
J. Med. Chem.
Galecto Biotech, Gothenburg, SE




Compound 39 | GCN2

oral GCN2 kinase inhibitor
TGI in LL2 syngeneic mouse model
SAR opt. from literature starting point
J. Med. Chem.
RAPT Therapeutics, South San Francisco, CA




GST-HG131 | PAPD5/PAPD7

oral HBV antigen inhibitor
Ph. I candidate for hepatitis B
SAR opt. of a previously disclosed inhibitor
Bioorganic Med. Chem. Lett.
WuXi AppTec, Shanghai, CN




Neflamapimod | p38 α kinase

oral p38 α kinase inhibitor
Ph. II candidate in neurology
from SBDD and opt.
Nat. Commun.
EIP Pharma Inc, Boston, MA /
Vertex, Cambridge, MA




AZD1390 | ATM kinase

oral ATM kinase inhibitor
Ph. I candidate oncology
biochem-based screen. and BBB penetration opt
J. Pharmacol. Exp. Ther.
AstraZeneca, Cambridge, UK




Upacicalcet | CaSR

IV CaSR agonist
Ph. III candidate in secondary hyperparathyroidism
identified from "kokumi-flavor" studies of peptides
Mol. Pharmacol.
Sanwa Kagaku Kenkyusho, Mie, JP




CH7057288 | TRK

oral pan-TRK inhibitor
tumor regression NIH3T3/NTRK1 mice models
from in-house library screening and SBDD
J. Med. Chem.
Chugai Pharmaceutical, Shizuoka, JP



ICeD-2 | DPP9

oral DPP9 inhibitor
in vitro synergy with NNRTI for HIV
from 250k compd phenotypic screen
ACS Chem. Biol.
Merck, Rahway, NJ



Vadadustat | HIF-PHD

oral HIF-PHD enzyme inhibitor
Ph. III candidate for anemia in CKD
carboxylic acid class of HIF-PHD inhibitors
J. Pharmacol. Exp. Ther.
Akebia Therapeutics, Cambridge, MA